

CORRIGENDUM

Economic evaluation of posaconazole vs fluconazole in the prevention of invasive fungal infections in patients with GVHD following haematopoietic SCT

R de la Cámara, I Jarque, MA Sanz, S Grau, MA Casado, FJ Sabater and E Carreras

Bone Marrow Transplantation (2010) **45**, 966; doi:10.1038/bmt.2009.352

Correction to: *Bone Marrow Transplantation* (2010) **45**, 925–932; doi:10.1038/bmt.2009.272; published online 5 October 2009

Since the publication of the above article, the authors have noticed that the correct conflict of interest statement was not included in their paper. This statement should have read:

Conflict of interest

R de la Cámara, I Jarque, MA Sanz and E Carreras have received honoraria for speaking at the symposia organized on behalf of Pfizer, Merck Sharp & Dohme (MSD), Schering-Plough and Gilead Science. S Grau has

received honoraria for speaking at the symposia organized on behalf of Pfizer. RC and MS have sat on the advisory boards on antifungal agents for Pfizer, MSD, Schering-Plough and Gilead Science. EC has sat on the advisory boards on antifungal agents for Pfizer, MSD and Schering-Plough. IJ has sat on the advisory boards on antifungal agents for MSD. MA Casado has served as an external consultant for Schering-Plough SA, and FJ Sabater was an employee of the company at the time of submission.

The authors would like to apologize for any inconvenience caused.